A. Mazzola

发表

Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.

S. Chandarlapaty, J. Baselga, J. Katzenellenbogen, 2017, Cancer discovery.

Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib

M. Rolfe, G. Weatherhead, Julie Zhang, 2006, Molecular Cancer Therapeutics.

Novel Neutralizing Hedgehog Antibody MEDI-5304 Exhibits Antitumor Activity by Inhibiting Paracrine Hedgehog Signaling

E. Hurt, R. Hollingsworth, Youzhen Wang, 2013, Molecular Cancer Therapeutics.

Running title : Pharmacology of SERD inhibitor in breast cancer models

Graham, A. Rabow, R. A. Norman, 2016 .

457 Preclinical pharmacology of AZD5312, a generation 2.5 antisense oligonucletotide targeting the androgen receptor with differentiated activity from enzalutamide

M. Jo, B. Davies, D. Blakey, 2014 .

Lipid nanoparticles incorporating a GalNAc ligand enable in vivo liver ANGPTL3 editing in wild-type and somatic LDLR knockout non-human primates

K. G. Rajeev, S. Kathiresan, K. Musunuru, 2021 .

In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates

Nicole M. Gaudelli, Christopher J. Cheng, K. G. Rajeev, 2021, Nature.

Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers

N. Camp, S. Barry, O. Delpuech, 2016, Oncotarget.

Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations

E. Hurt, R. Hollingsworth, S. Fawell, 2016, Oncotarget.

Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers

S. Grosskurth, S. Fawell, C. Reimer, 2014, Oncotarget.

Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models

S. Kathiresan, Scott B Vafai, Andrew M. Bellinger, 2022, Circulation.

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.

A. Rabow, G. Walker, R. A. Norman, 2016, Cancer research.

Abstract DDT01-03: Discovery and pre-clinical pharmacology of AZD9496: An oral, selective estrogen receptor down-regulator (SERD)

A. Rabow, D. M. Andrews, G. Walker, 2015 .

Abstract 3572: AZ5576, a novel potent and selective CDK9 inhibitor, induces rapid cell death and achieves efficacy in multiple preclinical hematological models

L. Drew, C. D’Cruz, A. Borodovsky, 2016 .

GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy

K. G. Rajeev, S. Kathiresan, K. Musunuru, 2023, Nature communications.